General Information of Drug (ID: DMEPHMR)

Drug Name
BCMA-CS1 cCAR Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMEPHMR

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Idecabtagene vicleucel DMP1QTS Multiple myeloma 2A83 Approved [2]
Belantamab mafodotin DMBT3AI Multiple myeloma 2A83 Approved [3]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [4]
Teclistamab DMGR8JI Multiple myeloma 2A83 Approved [5]
Ciltacabtagene autoleucel DMU2J7Y Multiple myeloma 2A83 Phase 3 [6]
Bb2121 DMB0UF9 Multiple myeloma 2A83 Phase 2 [7]
LCAR-B38M CAR-T Cell DMQZJNA Multiple myeloma 2A83 Phase 2 [8]
Descartes-08 DM63P1W Multiple myeloma 2A83 Phase 2 [9]
Descartes-11 DM1UO4S Multiple myeloma 2A83 Phase 2 [10]
CART-19/BCMA DMVW1GY Multiple myeloma 2A83 Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Elotuzumab DMEYHG9 Multiple myeloma 2A83 Approved [12]
PVX-410 DM6DK9A Multiple myeloma 2A83 Phase 2 [12]
CS1-CAR T Therapy DMU8OCN Plasma cell myeloma 2A83.1 Phase 1 [13]
ABBV-838 DMZM0T8 Multiple myeloma 2A83 Phase 1 [7]
MB-104 DMRP4BM Multiple myeloma 2A83 Phase 1 [14]
UCARTCS1 DM2Y4D7 Multiple myeloma 2A83 Phase 1 [15]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell maturation protein (TNFRSF17) TTZ3P4W TNR17_HUMAN Not Available [1]
SLAM family member 7 SLAMF7 (CS1) TT7ILZ1 SLAF7_HUMAN Not Available [1]

References

1 ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
5 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761291.
6 ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
9 ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
10 Clinical pipeline report, company report or official report of Cartesian Therapeutics.
11 ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
12 Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228.
13 ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
14 Clinical pipeline report, company report or official report of Mustang Bio.
15 ClinicalTrials.gov (NCT04142619) Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01). U.S. National Institutes of Health.